Gilead Sciences Reports ZUMA-5 Results for Yescarta in Follicular Lymphoma

Gilead Sciences today announced results from the Phase 2 ZUMA-5 trial evaluating Yescarta (axicabtagene ciloleucel) in patients with relapsed or refractory follicular lymphoma. The trial demonstrated an overall response rate of 94%, with a complete response rate of 79%. These results led to FDA approval of Yescarta for relapsed/refractory follicular lymphoma.